Skip to main content
Defiance International

Published study records

Study records for LL-37

Study records describe published research and its limitations. They do not establish efficacy, safety, or suitability for any use.

Study record counts

2,177 study records.

92 evidence-verified · 829 citation-verified · 1,253 identifier-confirmed · 3 citation-only

Listed by tier, then records with a public summary first, then publication year, newest first, undated last.

Verified records by research setting

  • In vitro: 547
  • In vivo/preclinical: 147
  • Review/meta-analysis: 109
  • Other: 0
Filter study recordsReset filters

Filtered results

Study type not established · Verification: PMID confirmed at PubMed

  • 2022

Chicken cathelicidin-2 promotes NLRP3 inflammasome activation in macrophages.

Veterinary research · 2022

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

PMID confirmed at PubMed. The PMID shown was confirmed at PubMed on 2026-09-14: PubMed held a record under this identifier. This check confirms the identifier only, not the study type, the findings, or any relevance to a chemical sequence. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type not established · Verification: DOI confirmed at Crossref

  • 2022

Niacinamide enhances cathelicidin mediated SARS-CoV-2 membrane disruption

2022

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

DOI confirmed at Crossref. The DOI shown was confirmed at Crossref on 2026-09-14: Crossref held a registration for this identifier. This check confirms the identifier only, not the kind of work, the findings, or any relevance to a chemical sequence. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type not established · Verification: PMID confirmed at PubMed

  • 2022

LL-37, a Multi-Faceted Amphipathic Peptide Involved in NETosis.

Cells · 2022

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

PMID confirmed at PubMed. The PMID shown was confirmed at PubMed on 2026-09-09: PubMed held a record under this identifier. This check confirms the identifier only, not the study type, the findings, or any relevance to a chemical sequence. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type not established · Verification: PMID confirmed at PubMed

  • 2022

LL-37-Coupled Porous Composite Scaffold for the Treatment of Infected Segmental Bone Defect.

Pharmaceutics · 2022

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

PMID confirmed at PubMed. The PMID shown was confirmed at PubMed on 2026-09-09: PubMed held a record under this identifier. This check confirms the identifier only, not the study type, the findings, or any relevance to a chemical sequence. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type not established · Verification: PMID confirmed at PubMed

  • 2022

Application of Antimicrobial Peptide LL-37 as an Adjuvant for Middle East Respiratory Syndrome-Coronavirus Antigen Induces an Efficient Protective Immune Response Against Viral Infection After Intranasal Immunization.

Immune network · 2022

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

PMID confirmed at PubMed. The PMID shown was confirmed at PubMed on 2026-09-09: PubMed held a record under this identifier. This check confirms the identifier only, not the study type, the findings, or any relevance to a chemical sequence. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type not established · Verification: PMID confirmed at PubMed

  • 2022

Role of Differences in Respiratory Syncytial Virus F and G Glycoproteins on Susceptibility to Inactivation by Antimicrobial Peptides LL-37 and Human Beta-Defensins.

Viral immunology · 2022

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

PMID confirmed at PubMed. The PMID shown was confirmed at PubMed on 2026-09-09: PubMed held a record under this identifier. This check confirms the identifier only, not the study type, the findings, or any relevance to a chemical sequence. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type not established · Verification: PMID confirmed at PubMed

  • 2022

The antimicrobial peptide cathelicidin drives development of experimental autoimmune encephalomyelitis in mice by affecting Th17 differentiation.

PLoS biology · 2022

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

PMID confirmed at PubMed. The PMID shown was confirmed at PubMed on 2026-09-14: PubMed held a record under this identifier. This check confirms the identifier only, not the study type, the findings, or any relevance to a chemical sequence. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type not established · Verification: PMID confirmed at PubMed

  • 2022

Membrane Activity of LL-37 Derived Antimicrobial Peptides against Enterococcus hirae: Superiority of SAAP-148 over OP-145.

Biomolecules · 2022

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

PMID confirmed at PubMed. The PMID shown was confirmed at PubMed on 2026-09-09: PubMed held a record under this identifier. This check confirms the identifier only, not the study type, the findings, or any relevance to a chemical sequence. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type not established · Verification: PMID confirmed at PubMed

  • 2022

The human cathelicidin hCAP-18 in serum of children with haemato-oncological diseases.

British journal of haematology · 2022

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

PMID confirmed at PubMed. The PMID shown was confirmed at PubMed on 2026-09-14: PubMed held a record under this identifier. This check confirms the identifier only, not the study type, the findings, or any relevance to a chemical sequence. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type not established · Verification: PMID confirmed at PubMed

  • 2022

Anti-Pythium insidiosum activity of MSI-78, LL-37, and magainin-2 antimicrobial peptides.

Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2022

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

PMID confirmed at PubMed. The PMID shown was confirmed at PubMed on 2026-09-09: PubMed held a record under this identifier. This check confirms the identifier only, not the study type, the findings, or any relevance to a chemical sequence. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type not established · Verification: PMID confirmed at PubMed

  • 2022

Inhibitory Effects of Polymyxin B and Human LL-37 on the Flagellin Expression in Vibrio vulnificus.

Biocontrol science · 2022

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

PMID confirmed at PubMed. The PMID shown was confirmed at PubMed on 2026-09-09: PubMed held a record under this identifier. This check confirms the identifier only, not the study type, the findings, or any relevance to a chemical sequence. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type not established · Verification: PMID confirmed at PubMed

  • 2022

Injectable hydrogel as a carrier of vancomycin and a cathelicidin-derived peptide for osteomyelitis treatment.

Journal of biomedical materials research. Part A · 2022

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

PMID confirmed at PubMed. The PMID shown was confirmed at PubMed on 2026-09-14: PubMed held a record under this identifier. This check confirms the identifier only, not the study type, the findings, or any relevance to a chemical sequence. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.